866-997-4948(US-Canada Toll Free)

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 81 Pages

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Pipeline Review, H2 2017

Summary

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 6-Pipeline Review, H2 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimers disease and other forms of dementia and obesity. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 2, 11 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Metabolic Disorders which include indications Alzheimers Disease, Schizophrenia, Psychiatric Disorders, Anxiety Disorders, Mild Cognitive Impairment, Neurology, Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (Manic Depression), Cognitive Disorders, Dementia, Depression, Lewy body Dementia, Major Depressive Disorder, Movement Disorders, Neurodegenerative Diseases, Obesity, Parkinsons Disease, Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Tourette Syndrome and Vascular Injury.

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
- The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Overview
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Companies Involved in Therapeutics Development
Acorda Therapeutics Inc
Adamed Sp z oo
Avineuro Pharmaceuticals Inc
Axovant Sciences Ltd
Celon Pharma SA
Galenea Corp
H. Lundbeck A/S
Reviva Pharmaceuticals Inc
Suven Life Sciences Ltd
Teva Pharmaceutical Industries Ltd
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Drug Profiles
ADN-1184-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-2013-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-3662-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-3208-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-0189-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-101-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-211-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-3085-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-3205-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-322-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-492-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
intepirdine-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
landipirdine-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LuAF-35700-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 for Alzheimers Disease-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 Receptor for Mood Disorders-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target 5-HT2C and 5-HT6 Receptor for Schizophrenia-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-501-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-502-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-507-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-512-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Dormant Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Discontinued Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Product Development Milestones
Featured News & Press Releases
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
Sep 26, 2017: Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimers Disease
Sep 26, 2017: Set-back for Alzheimers drug in final stage trial
Jul 19, 2017: New Preclinical Data for Intepirdine Suggests Potential Neuroprotective Properties
Dec 09, 2016: Axovant Sciences Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimers Disease Maintain Independence Longer
Dec 09, 2016: Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimers Disease Maintain Independence Longer
Dec 05, 2016: Axovant Sciences to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimers Disease at CTAD 2016
Dec 05, 2016: Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimers Disease at CTAD 2016
Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
Sep 26, 2016: Axovant Sciences Receives FDA Fast-Track Designation for Intepirdine as an Investigational Treatment for Dementia with Lewy Bodies
Jul 18, 2016: Axovant Sciences Announces Presentations on Intepirdine and Sponsored Symposium at the 2016 Alzheimers Association International Conference
May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia
Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia
Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Acorda Therapeutics Inc, H2 2017
Pipeline by Adamed Sp z oo, H2 2017
Pipeline by Avineuro Pharmaceuticals Inc, H2 2017
Pipeline by Axovant Sciences Ltd, H2 2017
Pipeline by Celon Pharma SA, H2 2017
Pipeline by Galenea Corp, H2 2017
Pipeline by H. Lundbeck A/S, H2 2017
Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Pipeline by Suven Life Sciences Ltd, H2 2017
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Dormant Products, H2 2017 (Contd..2), H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *